A major regulatory achievement has been reached for a next-generation RNAi therapy targeting common KRAS-driven cancers with substantial unmet medical requirements. This advancement allows for the progression into clinical-stage development. The innovative treatment features a systemic delivery approach and aims to address prevalent cancers.